Boehringer Ingelheim and Lilly initiate post-marketing trial with a planned enrollment of more than 8,000 adults with type 2 diabetes in 24 countries (Lilly)
Diabetes News Service
Glycosmedia App
A Glycosmedia iPhone/iPad App is available FREE from the iTunes store.
Sponsorship and Advertising
For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com
HONcode Standard
This site complies with the HONcode standard for trustworthy health information: verify here.
